Broadening Awareness Around DLL3-Directed Therapies in Small Cell Lung Cancer and Neuroendocrine Carcinomas

Solange Peters, MD, PhD, discusses findings for obrixtamig plus atezolizumab/chemotherapy in first-line extensive-stage small cell lung cancer.

Balazs Halmos, MD, discusses the differences in presentation and available treatments between neuroendocrine tumors and neuroendocrine carcinomas.

Balazs Halmos, MD, discusses the DLL3-targeted BiTE obrixtamig for the treatment of patients with extrapulmonary neuroendocrine carcinoma.

Jason S. Starr, DO, discusses DLL3 as a treatment target in extrapulmonary neuroendocrine carcinomas.

Obrixtamig combined with topotecan demonstrated favorable safety and early efficacy in relapsed/refractory SCLC.

Martin Wermke, MD, discusses obrixtamig in combination with topotecan for the treatment of patients with advanced small cell lung cancer.

Jonathan Strosberg, MD, discusses how the phase 2 DAREON-5 trial could address questions about the use of DLL3/CD3-targeted agents in SCLC and other NECs.

The DLL3- and CD3-targeted BiTE obrixtamig is being evaluated in patients with SCLC and other neuroendocrine cancers in the phase 2 DAREON-5 study.